Skip to main content
. 2022 Jul 27;78(1):202–213. doi: 10.1111/all.15443

TABLE 1.

Characteristics of patients and their hypersensitivity reactions

Total Grade 1 Grade 2 Grade 3 Anaphylaxis a p‐Value b
Number 150 38 83 29 112
Gender (female) 61% 68% 59% 58% 62% .3394
Age (years), mean (SD) 39.5 ± 18.3 46.0 ± 18.8 34.4 ± 16.9 42.8 ± 18.8 37.3 ± 17.6 .0382*
Atopy 49% 29% 58% 48% 55% .0083*
Basal Allergies 46% 29% 58% 48% 55% .0083*
Asthma 27% 13% 35% 21% 31% .0339*
Rhinitis 37% 21% 47% 31% 43% .0197*
Atopic dermatitis 6% 0% 6% 14% 8% .1157
Trigger
Drug 66% 100% 52% 62% 55% <.0001*
AINES 45% 50% 47% 28% 41% .3504
Antibiotics 37% 42% 34% 33% 34% .4348
Contrasts 5% 3% 5% 11% 7% .4496
Chemotherapies 7% 0% 7% 22% 11% .0374*
Others c 6% 5% 7% 6% 7% .7387
Food 29% 0% 40% 35% 38% <.0001*
Nuts 23% 0% 21% 30% 23% .0008*
Fish/Seafood 23% 0% 25% 20% 23% .0008*
Fruits 14% 0% 15% 10% 14% .0122*
Milk 19% 0% 21% 10% 19% .0013*
Egg 14% 0% 12% 20% 14% .0122*
Others d 7% 0% 6% 10% 7% .1921
Others e 5% 0% 8% 3% 7% .1921
Symptoms
Cutaneous 89% 92% 87% 90% 88% .5698
Mucosal 49% 42% 53% 45% 51% .4528
Digestive 37% 0% 49% 52% 50% <.0001*
Respiratory 64% 0% 88% 79% 86% <.0001*
Neurological 19% 0% 19% 41% 25% .0004*
Cardiovascular 23% 0% 11% 86% 30% <.0001*
Treatment f 62% 24% 75% 73% 79% <.0001*
Epinephrine 61% 11% 61% 83% 67% <.0001*
H1R antagonist 81% 100% 79% 78% 79% .0013*
H2R antagonist 18% 11% 11% 39% 19% .3173
Corticosteroids 80% 100% 75% 83% 77% .0008*
β2‐adrenergic agonist 17% 0% 20% 17% 19% .0051*

Abbreviations: AINES, non‐steroidal anti‐inflammatory drugs; H1R, histamine type 1 receptor; H2R, histamine type 2 receptor; SD, standard deviation.

a

Patients with Grade 2 and Grade 3 reactions.

b

Statistical differences between patients with Grade 1 events and those with anaphylaxis (*p value < .05).

c

Anaphylaxis induced by analgesics, anaesthetics, proton‐pump inhibitors or angiotensin‐converting‐enzyme inhibitors.

d

Anaphylaxis induced by mustard and honey.

e

Anaphylaxis induced by vaccines, insect stings or idiopathic.

f

Percentage of patients treated prior to acute sample collection in each group and treatments administered. The remaining patients received treatment after obtaining the sample.